BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 33547983)

  • 1. Tumor and Systemic Immunomodulatory Effects of MEK Inhibition.
    Dennison L; Mohan AA; Yarchoan M
    Curr Oncol Rep; 2021 Feb; 23(2):23. PubMed ID: 33547983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors.
    Grimaldi AM; Simeone E; Festino L; Vanella V; Strudel M; Ascierto PA
    Am J Clin Dermatol; 2017 Dec; 18(6):745-754. PubMed ID: 28537004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MEK inhibitors for the treatment of non-small cell lung cancer.
    Han J; Liu Y; Yang S; Wu X; Li H; Wang Q
    J Hematol Oncol; 2021 Jan; 14(1):1. PubMed ID: 33402199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity.
    Yarchoan M; Mohan AA; Dennison L; Vithayathil T; Ruggieri A; Lesinski GB; Armstrong TD; Azad NS; Jaffee EM
    PLoS One; 2019; 14(10):e0224600. PubMed ID: 31671149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade.
    Shin MH; Kim J; Lim SA; Kim J; Lee KM
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in
    Sun C; Fang Y; Yin J; Chen J; Ju Z; Zhang D; Chen X; Vellano CP; Jeong KJ; Ng PK; Eterovic AKB; Bhola NH; Lu Y; Westin SN; Grandis JR; Lin SY; Scott KL; Peng G; Brugge J; Mills GB
    Sci Transl Med; 2017 May; 9(392):. PubMed ID: 28566428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
    Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L
    J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
    Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
    Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MEK inhibitors under development for treatment of non-small-cell lung cancer.
    Kim C; Giaccone G
    Expert Opin Investig Drugs; 2018 Jan; 27(1):17-30. PubMed ID: 29216787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
    Temraz S; Mukherji D; Shamseddine A
    Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
    Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
    Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.
    Liu C; Lu H; Wang H; Loo A; Zhang X; Yang G; Kowal C; Delach S; Wang Y; Goldoni S; Hastings WD; Wong K; Gao H; Meyer MJ; Moody SE; LaMarche MJ; Engelman JA; Williams JA; Hammerman PS; Abrams TJ; Mohseni M; Caponigro G; Hao HX
    Clin Cancer Res; 2021 Jan; 27(1):342-354. PubMed ID: 33046519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel mitogen-activated protein kinase kinase inhibitors.
    Chapman MS; Miner JN
    Expert Opin Investig Drugs; 2011 Feb; 20(2):209-20. PubMed ID: 21235429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MEK inhibitors in oncology: a patent review (2015-Present).
    Mahapatra DK; Asati V; Bharti SK
    Expert Opin Ther Pat; 2017 Aug; 27(8):887-906. PubMed ID: 28594589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.
    Hatzivassiliou G; Haling JR; Chen H; Song K; Price S; Heald R; Hewitt JF; Zak M; Peck A; Orr C; Merchant M; Hoeflich KP; Chan J; Luoh SM; Anderson DJ; Ludlam MJ; Wiesmann C; Ultsch M; Friedman LS; Malek S; Belvin M
    Nature; 2013 Sep; 501(7466):232-6. PubMed ID: 23934108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to MEK inhibitors: should we co-target upstream?
    Poulikakos PI; Solit DB
    Sci Signal; 2011 Mar; 4(166):pe16. PubMed ID: 21447797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity.
    Hong A; Piva M; Liu S; Hugo W; Lomeli SH; Zoete V; Randolph CE; Yang Z; Wang Y; Lee JJ; Lo SJ; Sun L; Vega-Crespo A; Garcia AJ; Shackelford DB; Dubinett SM; Scumpia PO; Byrum SD; Tackett AJ; Donahue TR; Michielin O; Holmen SL; Ribas A; Moriceau G; Lo RS
    Cancer Discov; 2021 Mar; 11(3):714-735. PubMed ID: 33318037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
    Kelley MC
    Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
    Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.